HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2006.067512v1 52/8/1510    most recent Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Kong, S.-Y. Articles by Ro, J. Search for Related Content PubMed PubMed Citation Articles by Kong, S.-Y. Articles by Ro, J. Related Collections Molecular Diagnostics and Genetics Cancer Diagnostics (since 2002) Proteomics and Protein Markers Drug Monitoring and Toxicology

Predicting Tissue HER2 Status Using Serum HER2 Levels in Patients with Metastatic Breast Cancer

¹ Research Institute & Hospital, National Cancer Center, Goyang-si, Gyeonggi-do, Korea.

^aAddress correspondence to this author at: Center for Breast Cancer, National Cancer Center, 809, Madu-dong, Ilsan-gu, Goyang-si, Gyeonggi-do, 411-769, Republic of Korea. Fax 82-31-920-1520; e-mail jungsro{at}ncc.re.kr.

Background: Immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) are reliable ways to identify overexpression or amplification of the HER-2/neu (HER2, symbol ERBB2) gene, but each technique requires a high-quality tissue sample, which may not be available. We investigated whether serum concentrations of the HER2 extracellular domain (ECD) can be used as an alternative to tissue HER2 status in metastatic breast cancer, and we defined an optimal decision-level concentration of serum HER2 for prediction of tissue HER2 status.

Methods: In 195 patients with metastatic breast cancer, we determined HER2 expression by IHC and performed FISH analysis on tumors for which IHC staining was graded as 2+. We measured serum HER2 by immunoassay and used ROC curve analysis to determine optimal serum HER2 ECD concentrations for differentiation between positive and negative HER2 status.

Results: IHC results were 0/1+ for 30 (15%) of the patients, 2+ for 89 (46%), and 3+ for 76 (39%). FISH revealed HER2 amplification in 19 (21%) of the IHC 2+ tumors. Mean (SE) serum HER2 ECD was 22.2 (5.1) µg/L in the tissue HER2-negative group, significantly lower than the concentration of 363 (96) µg/L in the tissue HER2-positive group (P <0.0001). ROC curve analysis showed 95% specificity and 62% sensitivity for tissue HER2 positivity at 37 µg/L of serum HER2.

Conclusion: To use serum HER2 concentration as an alternative to direct determination of tissue HER2 status, we suggest 37 µg/L as a cutoff for predicting positive tissue HER2 with 95% specificity. Sensitivity, however, is low.

The following articles in journals at HighWire Press have cited this article:

				V. Ludovini, S. Gori, M. Colozza, L. Pistola, E. Rulli, I. Floriani, E. Pacifico, F. R. Tofanetti, A. Sidoni, C. Basurto, et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival Ann. Onc., May 1, 2008; 19(5): 883 - 890. [Abstract] [Full Text] [PDF]

				S. A. Perez, M. V. Karamouzis, D. V. Skarlos, A. Ardavanis, N. N. Sotiriadou, E. G. Iliopoulou, M. L. Salagianni, G. Orphanos, C. N. Baxevanis, G. Rigatos, et al. CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu (HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients Clin. Cancer Res., May 1, 2007; 13(9): 2714 - 2721. [Abstract] [Full Text] [PDF]